Tone mix
Week by week 40 weeks
Share of REGENXBIO Inc.'s 183 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Nov 17, 2025 · tone -66REGENXBIO (NASDAQ:RGNX) Cut to Sell at Wall Street Zen-94
- Week of Oct 5, 2026 · tone +50REGENXBIO (NASDAQ:RGNX) Upgraded at Mizuho+80
- Week of Jan 26, 2026 · tone -79REGENXBIO Shares Decline 17% After FDA Imposed Clinical Holds On Gene Therapy Programs-77
- Week of Sep 21, 2026 · tone +50REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting+75
- Week of Dec 29, 2025 · tone +100REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages+70
- Week of Feb 2, 2026 · tone -75Clinical Trial Holds Cast Doubt on Approval Chances of Regenxbio Gene Therapy for Rare Disease-57
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about REGENXBIO Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 1 | 0 |
| Last 30 sessions | 6 | +33 |
| Last 90 sessions | 34 | -7 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 29, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 1 outletREGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational HighlightsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 1 outletREGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 8, 2026
2 headlines, average tone +50: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.themarketsdaily.com · 1 outletREGENXBIO (NASDAQ:RGNX) Upgraded at MizuhoPositive
- www.dailypolitical.com · 1 outletContrasting Cue Biopharma (NASDAQ:CUE) & REGENXBIO (NASDAQ:RGNX)Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| REGENXBIO (NASDAQ:RGNX) Upgraded at Mizuho | www.themarketsdaily.com | 1 | Positive |
| Contrasting Cue Biopharma (NASDAQ:CUE) & REGENXBIO (NASDAQ:RGNX) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, September 25, 2026
2 headlines, average tone +50: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.prnewswire.com · 2 outletsREGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingPositive
- www.dailypolitical.com · 1 outletComparing REGENXBIO (NASDAQ:RGNX) and Myriad Genetics (NASDAQ:MYGN)Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting | www.prnewswire.com | 2 | Positive |
| Comparing REGENXBIO (NASDAQ:RGNX) and Myriad Genetics (NASDAQ:MYGN) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, September 8, 2026
2 headlines, average tone -50: 0 positive, 1 neutral and 1 negative. Showing all 2.
- www.insidermonkey.com · 2 outletsRegenxbio's Gene Therapy Faces Another FDA Setback in Hunter SyndromeNegative
- www.prnewswire.com · 1 outletREGENXBIO to Participate in Upcoming Investor ConferencesNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Regenxbio's Gene Therapy Faces Another FDA Setback in Hunter Syndrome | www.insidermonkey.com | 2 | Negative |
| REGENXBIO to Participate in Upcoming Investor Conferences | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about REGENXBIO Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.